Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Dare Bioscience Q2 EPS $(0.45) Beats $(0.61) Estimate

Author: Benzinga Newsdesk | August 14, 2025 04:03pm
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.61) by 26.83 percent. This is a 129.61 percent decrease over earnings of $1.52 per share from the same period last year.

Posted In: DARE

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist